Navigation Links
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
Date:9/30/2013

mation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. These statements include, but are not limited to, Omeros' expectations regarding a Phase 2 clinical trial later this year; the clinical therapeutic index or "safety factor" of OMS824; that OMS824 has the potential to improve the cognitive and psychiatric abnormalities as well as the movement disorders associated with Huntington's disease; and regarding the potential therapeutic benefits and qualities of OMS824. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities a
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13
... May 7, 2012 A new analysis concludes that rituximab, ... treatment responses lasting at least five years in approximately one ... of bleeding due to chronic immune thrombocytopenic purpura (ITP). In ... Blood , the Journal of the American Society ...
... Mass., May 7, 2012  CardioFocus, Inc., developer of ... treatment of atrial fibrillation (AF), announces that its ... the scientific sessions and during a private academic ... Society,s 33rd Annual Scientific Sessions, May 9-12 in ...
Cached Medicine Technology:Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 2Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 3Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 2Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 3
(Date:9/19/2014)... biosensor made from the wonder material graphene has been ... of developing cancer. , The biosensor has been ... than bioassay tests currently in use, and was able ... up the possibility of a rapid, point-of-care diagnostic tool ... 19 September, in IOP Publishing,s journal 2D Materials ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... integral part of the medical imaging market, are engineered ... technology developments over the past three decades have expanded ... From barium and iodine based agents used for over ... nanoparticles and radiopharmaceuticals, imaging agents have witnessed sea changes, ...
(Date:9/19/2014)... 2014 The Nordic ... style of eating, is making its way ... Doc’s medical weight loss programs, ... good food which leads to improved health. ... patients to understand how diet can impact ...
(Date:9/19/2014)... Boston, MA (PRWEB) September 19, 2014 ... in the freight trucking industry increased their sales by ... like this from the trucking industry can be used ... is doing as a whole. This data has been ... to other forms of freight transportation. Other non-trucking data ...
(Date:9/19/2014)... September 19, 2014 Activz Whole-Food Nutrition ... Smoothie product, a new whole-food produce powder smoothie, ... Baltimore, MD. Activz Greens Smoothie is a ... one convenient – and absolutely delicious —Greens Smoothie. Details ... Baltimore, MD. , The new ...
Breaking Medicine News(10 mins):Health News:Graphene sensor tracks down cancer biomarkers 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3
... back in 2002, at the San Francisco's 2002 Gay Pride, ... campaign to popularize syphilis testing. ,In the above ... introduced to Gayville, encouraging the many hundreds of homo whores ... big-S. (Syphilis) ,Although many were not happy with ...
... Fresh bird flu outbreaks reported from Vietnam and South ... Ministry is fully stocked and ready to deal with ... ,The Ministry has a stock of 2.5 ... birds and 475,000 doses of influenza vaccines to be ...
... for patients in ICU by adhering to simple techniques ... infections. ICUs can become thoroughly aseptic by ensuring a ... catheters. A detailed report was made by experts on ... report are published in New England Journal of Medicine. ...
... surgery for his broken leg. Schwarzenegger broke his right femur ... surgery took place three days later and doctors used screws ... ,It is possible that the governor will attend ... ,Orthopaedic surgeon Kevin Ehrhart said: "He is ...
... few nonjudgmental counseling sessions can prompt women to both ... according to a new study//. ,Prenatal alcohol exposure ... developmental disabilities in the United States. This CDC study ... of an alcohol-exposed pregnancy. ,“A lot of ...
... the reason why the common parasite Toxoplasma,// does not ... others seriously ill. , ,Toxoplasma is a genus ... can also be passed on by many other warm-blooded ... which in normal circumstances is not harmful, but can ...
Cached Medicine News:Health News:Simple Steps to Safe Guard Patients from Bloodstream Infections in ICU 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 3
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
Medicine Products: